Rapid Identification of Malaria Vaccine Candidates Based on α-Helical Coiled Coil Protein Motif by Villard, Viviane et al.
Rapid Identification of Malaria Vaccine Candidates Based
on a-Helical Coiled Coil Protein Motif
Viviane Villard
1, George W. Agak
1,G e ´raldine Frank
1, Ali Jafarshad
2, Catherine Servis
1, Issa Ne ´bie ´
3, Sodiomon B. Sirima
3, Ingrid Felger
4, Myriam
Arevalo-Herrera
5, Socrates Herrera
5, Frederic Heitz
6, Volker Ba ¨cker
6, Pierre Druilhe
2, Andrey V. Kajava
6, Giampietro Corradin
1*
1Department of Biochemistry, University of Lausanne, Epalinges, Switzerland, 2Pasteur Institute, Paris, France, 3Centre National de Recherche et
Formation sur le Paludisme, Ouagadougou, Burkina Faso, 4Swiss Tropical Institute, Basel, Switzerland, 5Institute of Immunology, University of Valle,
Cali, Colombia, 6CRBM, CNRS, University of Montpellier, Montpellier, France
To identify malaria antigens for vaccine development, we selected a-helical coiled coil domains of proteins predicted to be
present in the parasite erythrocytic stage. The corresponding synthetic peptides are expected to mimic structurally ‘‘native’’
epitopes. Indeed the 95 chemically synthesized peptides were all specifically recognized by human immune sera, though at
various prevalence. Peptide specific antibodies were obtained both by affinity-purification from malaria immune sera and by
immunization of mice. These antibodies did not show significant cross reactions, i.e., they were specific for the original
peptide, reacted with native parasite proteins in infected erythrocytes and several were active in inhibiting in vitro parasite
growth. Circular dichroism studies indicated that the selected peptides assumed partial or high a-helical content. Thus, we
demonstrate that the bioinformatics/chemical synthesis approach described here can lead to the rapid identification of
molecules which target biologically active antibodies, thus identifying suitable vaccine candidates. This strategy can be, in
principle, extended to vaccine discovery in a wide range of other pathogens.
Citation: Villard V, Agak GW, Frank G, Jafarshad A, Servis C, et al (2007) Rapid Identification of Malaria Vaccine Candidates Based on a-Helical Coiled
Coil Protein Motif. PLoS ONE 2(7): e645. doi:10.1371/journal.pone.0000645
INTRODUCTION
Human Plasmodium falciparum (Pf) infection is a dramatic public
health problem. Today approximately forty percent of the world’s
population is at risk of malaria. Malaria causes more than 300
million acute clinical cases, and at least one million deaths
annually. Ninety percent of malaria deaths occur in sub-Saharan
African countries mostly among young children and pregnant
women (http://rbm.who.int). Thus, there is an urgent need of
a malaria vaccine. However, vaccine discovery, in general and
particularly in malaria, is still a very empirical process. In fact,
protective antigens do not bear any structural, physico-chemical or
sequence-related characteristics that would allow their identifica-
tion. For protective humoral responses, the only recognized
characteristics of antigens are their antigenicity/immunogenicity
and accessibility. In addition, the lack of surrogate markers of
protection renders the vaccine discovery process difficult and time
consuming. Hence, in spite of a constant and impressive progress
in molecular biology techniques and antigen identification and
expression [1,2], vaccine discovery is still labor-intensive, making
the approach fastidious, costly and poorly adapted to high-
throughput screening. Proper protein folding and solubility remain
a limitation in numerous cases. Thus, overcoming the bottlenecks
of manufacturing and identification of fragments/proteins, as
possible targets of a protective immune response still constitute
a scientific and technical challenge.
We addressed this challenge by combining bioinformatics,
chemical peptide synthesis and functional protection assays. We
focused on the search for a-helical coiled coil motifs that, in
general, do not exhibit a folding problem, and are a target of
effective antibodies for several current malaria vaccine candidates
(eg. LSA-1 [3], LSA-3 [4], MSP-3 [5], and MSP-6 [6] and other
pathogens [7]. MSP-1, another leading malaria vaccine [8], also
contains predicted a-helical coiled coil regions (unpublished
results). Our choice was based on the following considerations.
First, the a-helical coiled coil motif bears a characteristic seven
amino acid residue repeat (abcdefg)n with hydrophobic residues
located in a and d positions and hydrophilic residues generally
elsewhere. This motif can be easily identified by bioinformatic
analysis. Secondly, an important known characteristic of the a-
helical coiled coil domains is that, taken separately from the whole
protein, they frequently and readily fold into the same stable
oligomeric structure [9]. Thirdly, for this reason, the a-helical
coiled coil fragments are frequently recognized by conformational
dependent antibodies, and can similarly elicit antibodies reactive
with structurally ‘‘native’’ epitopes. In addition, these domains are
short (about 40 residues) and can be rapidly produced by chemical
synthesis. Furthermore, when the antibodies have an anti-parasite
biological activity, this designates the corresponding proteins/
fragments as potential, novel vaccine candidates to be further
developed and assessed. Here, we focus on the Pf parasite
erythrocytic stage, a target of protective antibodies and describe
a straightforward, rapid procedure based on bioinformatic analysis
of a-helical coiled-coil motifs and peptide synthesis.
RESULTS AND DISCUSSION
The screening of the Pf genome [10] using generalized sequence
profiles [11] identified several hundred proteins containing
putative a-helical coiled coil motifs. Through proteome and
transcriptome data [12–14] we assessed which of these molecules
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analysis/assessment identified over 100 segments associated with
this stage and displaying the putative a-helical coiled coil motifs
with high probability score (Table S1). Out of these a-helical coiled
coil fragments, in general 30–40 amino acids long, present either
in the same protein or in different ones, 95 were chemically
synthesized and HPLC purified. Among them, longer peptides (up
to 70 amino acids), which contained one or more a-helical coiled
coil domains, were also synthesized (antigenS 1, 12 and 83; Table
S1). The selected antigens were then tested in ELISA assays for
reactivity with three panels of sera obtained from adult donors
from Burkina Faso, Tanzania and Colombia, respectively. To our
surprise, all of the a-helical coiled coil fragments were antigenic,
though the prevalence of responders varied greatly (Tables 1 and
S1). In this manner, 71 proteins were identified whose lengths
varied from 200 to 10,000 amino acids. Twenty-one peptides with
the highest prevalence of responders and ELISA mean OD value
were selected for further studies. Variation in recognition among
the three panels of sera may be due to differences in the genetic
background of the hosts, of the parasites and, most likely, to
distinct malaria transmission conditions in the three regions. The
high level of recognition of the a-helical coiled coil motifs may be
explained by the fact that taken separately from the whole protein
these fragments readily fold into the same stable structure in
aqueous solution.
Indeed, circular dichroism (CD) studies of selected peptides
associated with biological activities (Tables 1 and 2) indicate that
they predominantly assume an a-helical conformation in water.
Peptides 14, 27 and 45 (Figure S1A) exhibit a CD pattern
characteristic of a high a-helical content, whereas the remaining
peptides show CD profiles similar to that shown for peptide 12
(Figure S1B) or intermediate between those shown in Figures S1A
and S1B characteristic of a partial a-helical organization. When
analyzed by size exclusion chromatography on FPLC columns,
peptides presented elution profiles between those exhibited by
chymotrypsin and ribonuclease (MW 24 and 13kDa, respectively).
The CD and size exclusion chromatography results suggest that
peptides adopt an a-helical coiled-coil structure, which need to be
unambiguously ascertained by NMR and ultra-centrifugation
studies.
To test the biological activity of peptide-specific antibodies, the
latter were purified by affinity chromatography using three serum
pools obtained from Papua New Guinean adults. The 3 serum
pools were first tested in ELISA assays against 21 peptides that
were the most antigenic (Table 1); from these, 18 peptide-specific
antibodies were purified from the most positive serum pool and
tested again in ELISA. These 18 antibodies all reacted with
parasite native proteins in infected red blood cells as shown by
IFAT (Figure 1A; Table 2). Reactivity was restricted to blood
stages, since the antibodies did not react with sporozoites stages
(data not shown), and this reactivity was also peptide-specific as
shown by IFAT competition assays with the corresponding peptide
(Figure 1A).
The specificity of the antibodies obtained was investigated in
detail, particularly since several peptides contain glutamic acid
(Glu)-rich sequences which are known to generate cross reactivity
among several malarial Glu-rich proteins [15]. Cross-reactions
were systematically investigated using each of the 18 affinity-
purified antibodies on each of the 18 peptides. Results show that -
with few exceptions- each antibody preferentially recognizes the
peptide against which antibodies were affinity-purified, i.e. they
are specific for the corresponding peptide (Table S2). To
determine if non-specific antibody binding to solid phase-adsorbed
antigens could be responsible for the rare cross-reactivities
detected, ELISA competition assays were performed. To this
end, binding of antibodies to the solid phase-adsorbed antigen was
competed against increasing concentrations of the homologous or
cross-reacting peptides. Only homologous peptides competed best
whereas peptides having sequence similarity did not (Figures 2A,
2B, and S2B), or at a much higher concentration (Figure S2A)
including the shorter Glu-rich peptides derived from the C-
terminus of peptide 27 and 45 (Figures 2A and 2B). Finally, the
pattern of recognition of peptides by the various sera tested, which
differ markedly from one to the other (data not shown), confirms
the above results i.e., specificity of antibodies to the corresponding
peptide.
Antibodies corresponding to the 18 selected peptides were tested
for direct and cell-mediated anti-parasite activity. Clinical
experiments have shown that the Antibody-Dependent Cell-
mediated Inhibition (ADCI) of P. falciparum malaria represents one
of the mechanisms controlling parasitemia and thereby clinical
manifestations in humans [16]. Twelve peptide-specific antibodies
proved able to induce a strong (more than 40%) and intermediate
(lower than 40%) monocyte-dependent parasite killing (Table 1),
whereas, in the absence of monocytes, no direct effect of antibodies
on parasite growth was observed. The effects were in the range
observed with antibodies from African adults who have the highest
natural protection known against malaria. Therefore peptide-
specific, human affinity-purified antibodies were functionally
effective as shown by their ability to react with parasite proteins
and to inhibit parasite growth. Thus, in vitro functional assays show
that peptide-specific antibodies elicited by natural exposure to the
parasite can induce protective mechanisms effective against
malaria.
Sixteen peptides -twelve targeted by ADCI positive antibodies
and four controls-were used to immunize CB6F1 mice (Table 2).
Eleven of them elicited an intermediate or high antibody response,
four of which also recognized the parasite protein in infected
erythrocytes as determined by IFAT (Figure 1B; Table 2). As seen
before for human antibodies, recognition was restricted to blood
stages since sporozoites were negative in IFAT assays (data not
shown) and by IFAT competition assays with the corresponding
peptide (Figure 1B). Anti-peptide 27 mouse antibodies, which are
positive in IFAT, are also specific for the homologous peptide 27
but not for the sequence related peptides 9, 12 and 45 (Table S2).
Thus, peptides, which were chosen for their propensity to form a-
helical coiled coil, can induce the production of antibodies that
recognize epitopes present in the native protein. Improvement of
the immunogenicity and structural specificity of the remaining
peptides might be achieved in the future by a) a short elongation at
the N- and C- terminal ends, b) stabilizing the a-helix as suggested
by Cooper et al. and Lu and Hodges [17,18] and/or c) use of other
adjuvants.
Genetic polymorphism in current vaccine candidates is a major
limitation to vaccine development. However available genotyping
studies of our peptide sequences in parasite isolates of worldwide
origin indicate very limited polymorphism (PlasmoDB 5.2, and
unpublished sequencing data). A few peptide DNA sequences
show deletion of one entire heptad repeat so that the shorter
region still preserves its potential for the a-helical coiled coil
formation.
With regard to the structural features and cellular location
prediction of the proteins corresponding to the peptides selected
for ADCI assays (Table 1), 15 of the proteins contain
a pentapeptide conforming to the PEXEL consensus [19, 20; 21,
22], but that none of these have a position within the amino acid
sequence that conforms to the location of known active PEXEL
motifs (see Materials and Methods and Table S3); 12 have trans-
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PLoS ONE | www.plosone.org 3 July 2007 | Issue 7 | e645membrane segments, and none of them has a GPI anchor. Only
one protein contains a signal sequence. Fourteen proteins are
predicted to be in the cytoplasm, one in the nucleus, one in the
mitochondria, and one in the peroxysomes (Table S3). The
prediction of the sub-cellular localization of these proteins should
be taken with caution because gene annotation is being constantly
updated and/or protein trafficking of the parasite is complex and
not fully elucidated [23].
Further investigations will be required to determine the actual
localization of the corresponding antigens. The predicted
localization is a priori surprising for molecules able to trigger
an ADCI activity. However, recent studies have shown that in
addition to merozoite surface proteins, soluble proteins released
at the time of schizont rupture were equally effective at
triggering ADCI provided they defined at least two epitopes
[24], which is the case for a-helical coiled coil heptad repeats.
Therefore, molecules expressing a trans-membrane domain that
can be exported to the parasite or host cell membrane, as well as
molecules present in the cytoplasm of maturing schizonts
and released by bursting schizonts can trigger antibodies to
cross-link Fc-c receptors on monocytes to achieve Pf parasite
killing.
In conclusion, an approach combining a genome-wide search
by bioinformatics of a-helical coiled coil protein motifs and
chemical synthesis can lead to the rapid identification and
development of new malaria vaccine candidates. In fact, this
approach is straightforward and easy to scale up; vaccine
formulations may comprise mixtures of peptides or single
constructs made up of several epitopes. In principle, this strategy
can be extended to the discovery of proteins and vaccine
candidates in other complex pathogens.
MATERIALS AND METHODS
Bioinformatics screening
The Pf 3D7 genome [10] was used for the bioinformatics analysis.
The generalized sequence profile method and the pftools package
[11] were used to search for the short a-helical coiled coil domains.
The coiled coil profiles were constructed using an alignment of
several amino acid sequences corresponding to the known coiled
coil domain. Two profiles containing four and five heptad repeats
were used for the analysis. The cut-off levels of the profiles were
chosen by tests performed against sequence database of proteins
with the known 3D structures. Subsequently, the coiled coil
Figure 1. Immunofluorescence microscopy analysis of Pf 3D7 parasites with peptide specific antibodies. Acetone/methanol-fixed schizonts and
merozoites were reacted with A: human peptide specific, affinity purified antibodies obtained with peptides 12 and 14 (Table 1) and B: sera from
mice immunized with peptide 27 (Table 1). Grey: bright field images; blue staining: indicates DAPI nuclear staining of schizont stage parasites; red
staining shows labeling of peptide specific antibodies by Cy3-conjugated anti-human or anti-mouse IgG specific antibody. Merge picture is an overlay
of the blue and red fluorescence channel.
doi:10.1371/journal.pone.0000645.g001
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presence of the characteristic heptad repeats. These proteins were
also analyzed by the COILS program [25].
The selected a-helical coiled coil containing proteins were
further tested on their possible surface location and GPI
anchoring by using the following programs: identification of
potential signal peptides, SecretomeP and SignalP (http://www.
cbs.dtu.dk/services/) [26]; transmembrane spanning regions
(TMPRED http://www.ch.embnet.org/software/TMPRED_
form.html and TMHMM http://www.cbs.dtu.dk/services/
TMHMM; [27,28]), and GPI-anchored proteins (http://mendel.
imp.univie.ac.at/sat/gpi/gpi_server.html; [29]) and prediction of
sub-cellular localization (pTARGET http://bioinformatics.
albany.edu/,ptarget; [30]). To identify the PEXEL-like motifs
in sequences of the selected proteins we used the following pattern
[KR][GAVLIMFWPSTCYNQ][LIA][GAVLIMFWPSTCYNQ]
[DEQ] that represents a combination of the PEXEL patterns
indicated in recent papers [21,22]. The presence of the identified
proteins in the asexual erythrocytic stages was also checked
using the published data on the transcriptome and proteome of
this stage of development of P. falciparum (www.PlasmoDB.org;
[31]).
Peptide synthesis
Peptides were synthesized on the Advanced ChemTech (Hatley St
George, UK) AC T348 Omega multi channel synthesizer and the
Applied Biosystem synthesizer 431A and 433A (Foster City, CA)
using solid-phase Fmoc chemistry. Crude peptides were purified
by RP-HPLC (C18 preparative column) and analyzed by mass
spectrometry (MALDI-TOF; Applied Biosystem, Foster City, CA).
Chemicals and solvents used for peptide synthesis were purchased
from Fluka (Buchs, Switzerland) and Novabiochem (Laufelfinger,
Switzerland).
Circular Dichroism Studies
Circular dichroism (CD) spectra of peptides were recorded on
a JASCO J-810 spectrometer (JASCO corporation, Tokyo, Japan)
equipped with a temperature controller and a 0.1 cm path length
cuvette. The measurements were made in water at pH 7.3 and
22uC and at a peptide concentration of 0.2 mg/ml.
Human Sera
The sera from Burkina Faso were collected in the village of
Goundry located in the central Mossi Plateau, between 15 and
50 km north of the capital Ouagadougou, in the province of
Oubritenga. The climate is characteristic of areas of Sudanese
savannah, with a dry season from November to May and a rainy
season from June to October. Malaria transmission is very high
during the rainy season and markedly seasonal. Ethical clearance
was obtained from the Ministry of Health, Burkina Faso. After
obtaining informed consent from parents and caretakers, hepa-
rinized venous blood samples were collected during a cross-
sectional survey during the malaria low transmission season 1998.
The Tanzanian sera came from a large-scale community based
study undertaken in Kikwalila village, Kilombero District,
Morogoro Region from 1982 to 1984. Blood samples from adults
(.15 years) were taken by finger prick and the serum was kept at –
70uC until use. Research and ethical clearance for the study was
obtained by the Tanzanian Commission for Science & Technol-
ogy.
The Colombian sera were collected in Buenaventura the main
port on the Colombian Pacific Coast after human informed
consent, during a cross sectional survey carried out from February
to May 2002 within the framework of a project supported by the
Colombian Research Council, COLCIENCIAS. The area has
unstable transmission of both P. falciparum and P. vivax malaria.
Ethical clearance to draw blood from human volunteers was
Table 2. Summary data of human and mouse antibodies.
..................................................................................................................................................
Peptides Proteins Ab titer IFAT (mouse Ab)
1 Prevalence
2 IFAT (Human Ab)
3
SGI
4 (%)
Rings Schizonts BF (%) Tz (%) Trophozoites Schizonts
8 PFB0145c 8100–72900 - - 70 36 ++ 0
9 100-100 - - 32 55 ++ 48
12 218700-218700 -/++ 65 74 ++ 50
13 100-100 - - 27 38 ++ 37
14 PFC0245c 2700-24300 - -/+ 41 40 ++ 71
27 MAL6P1.37 8100-24300 ++ 54 69 ++ 106
45 PF11_0207 100-100 - -/+ 70 62 ++ 36
52 PFL0770w 2700-8100 - - 51 36 ++ 19
54 MAL6P1.147 100-300 N D
5 ND 5 9 7 6 ++ 0
66 PFL0250w 900-8100 - - 51 74 ++ 56
76 MAL13P1.304 100-100 - - 57 50 ++ 35
77 PF08_0048 8100-218700 - - 54 79 ++ 36
79 PFB0315w 8100-218700 -/+ -/+ 76 93 ++ 16
80 MAL8P1.12 72900-218700 ++ 89 80 ++ 45
83 PFC0345w 72900-218700 ++ 51 75 ++ 0
90 PFD0520c 100-2700 - - 59 88 ++ 43
1Mouse antibodies were used at a dilution of 1:100
2,4For easier comparison, data are duplicated from Table 1. BF, Burkina Faso; Tz, Tanzania.
3Human purified antibodies were used at 5 mg/mL; IFAT was not performed on ring stages.
5Not Done
doi:10.1371/journal.pone.0000645.t002
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PLoS ONE | www.plosone.org 5 July 2007 | Issue 7 | e645obtained from the Institutional Review Board of Universidad del
Valle. Blood was taken by venipuncture into tubes containing
EDTA and sera fractionated and stored frozen until use.
The sera from adults from Papua New Guinea (PNG) pooled for
affinity purification were collected in the Maprik district of the
East Sepik Province, during a cross sectional survey in July 1992
within the framework of the Malaria vaccine Epidemiology and
Evaluation Project (MVEEP) supported by the United States
Agency for International Development [32]. The area is highly
endemic for malaria. Ethical clearance for MVEEP was obtained
from the PNG Medical Research Advisory Committee. Blood was
taken by venipuncture into tubes containing EDTA.
The pool of immune African globulins (PIAG) used for ADCI
was prepared from immune individuals living in endemic areas
and negative control IgG (N-IgG) was obtained from a pool of
more than 1000 French adult donors with no history of malaria.
Briefly, the IgG fractions from both positive and negative controls
were purified using a size exclusion TrisacrylH GF05M (Pall
BioSepraH; Pall life Sciences, NY) column followed by an ionic
exchange DEAE Ceramic HyperDH F column (Pall BioSepraH).
Purified IgG were then extensively dialyzed against RPMI and
kept at 4uC until use.
Mouse immunization
CB6F1 mice were injected 3 times with 20 mg of the indicated
peptide in Montanide ISA 720 at the base of the tail on day 1, 22
and 78. Bleeding was performed 10 days after the second and
third immunization.
ELISA
ELISA was performed according to Lopez et al. [33] and anti
human IgG-or anti mouse IgG conjugated to alkaline phospha-
tase was used (Sigma, St Louis, MO) as second antibody.
Individual human sera from 37, 42 and 39 adults donors from
Burkina Faso, Tanzania and Colombia respectively were used at
1:200 dilution. Serum was considered positive if the optical
density (OD) reading was higher than the mean OD value+3
Figure 2. ELISA inhibition assay using anti-human peptide specific antibodies. Binding of peptide specific antibodies to peptides 27 (A) and 45 (B)
absorbed on ELISA plates was inhibited by incubating specific antibodies (1–2 mg/ml) with peptides 27 or 45 or shorter fragments of the two,
designated as 27/short (NEEIEEIT) or 45/7 short (KEEIKE) (see Material and Methods).
doi:10.1371/journal.pone.0000645.g002
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PLoS ONE | www.plosone.org 6 July 2007 | Issue 7 | e645standard deviation (SD) of the negative controls (individual
s e r u ms a m p l e sf r o m8t o1 1n a ı ¨ve Swiss donors) or if the OD
ratio of the mean of duplicate experimental values to the mean
OD of the negative control was higher than 2. For mouse sera,
the end point value was determined as the last dilution of the
mean OD value+3 standard deviation (SD) of the negative
control (non immune sera).
ELISA Competition Assays
ELISA competition assays were performed by incubating either
each of the 18 selected human affinity-purified antibodies, or
antibodies elicited in mice, together with each of the 18 antigens
over the indicated range of concentrations for 30 minutes at room
temperature prior to addition to the ELISA peptide-coated plate
wells.
Antibody Purification by Affinity Chromatography
Antigen-Sepharose conjugate preparation: 5 mg of antigen was
dissolved in 1 mL of coupling buffer (0.1 M NaHCO3 containing
0.5 M NaCl, pH 8.0). The CNBr-sepharose 4B (Amersham
Bioscience AB, Uppsala, Sweden) was activated by swelling in
1 mM HCl and then washed with coupling buffer. The antigen
solution was added to the gel and the mixture was stirred for 1h at
RT. After the coupling reaction, excess antigen was washed away
with coupling buffer. The unreacted activated groups were
blocked by treatment with ethanolamine (0.25 M; pH 8.0) for
30 min at RT. The gel was then washed with sodium acetate
buffer (0.1 M; pH 4.0), followed by coupling buffer. The antigen-
sepharose beads were either used or stored at 4uC in PBS (1x)
containing 1 mM azide.
Isolation of specific antibody: Pooled human serum was diluted
five times with PBS (1x) containing 0.5 M sodium chloride and
mixed with antigen-sepharose conjugate. This mixture was then
stirred gently on a wheel O/N at 4uC. After centrifugation the
supernatant was collected and stored at 220uC for further use.
The antigen-sepharose beads were then washed with 5 mL of
trizma base TRIS (20 mM containing 0.5 M NaCl, pH 8.0) then
with 5 mL of TRIS (20 mM, pH 8.0). The elution of bound
antibody was achieved with glycine (0.1 M, pH 2.5). The fractions
obtained were instantly neutralized with TRIS (1 M, pH 8.0),
dialyzed against phosphate buffer (0.1M, pH 7.0) and the antibody
concentration was determined by the absorbance of the solution at
280 nm.
Indirect Fluorescence Antibody Test (IFAT)
Slides coated with Pf sporozoites were dried at RT for 30 minutes,
fixed with 100% acetone at 4uC for 10 minutes, washed 2 times in
PBS-0.05% Tween 20, dried carefully and blocked with 20 mL/
well of PBS-3% bovine serum albumin (BSA) for 30 minutes at
RT. Slides coated with Pf merozoites were fixed with 100%
acetone at 220uC for 15 minutes and dried O/N at RT. The
appropriate antibody or serum dilutions prepared in PBS-3% BSA
were distributed (10 mL/well) and incubated for 1h at RT in
a humid chamber. After washing with PBS-0.05% Tween-20, goat
anti-human or goat anti-mouse polyvalent immunoglobulins
conjugated to Cy3 (Molecular Probes) diluted 1/500 in PBS-3%
BSA or anti-human IgG (Fc specific) FITC conjugate (Sigma)
diluted 1/50 in Evans blue solution (1/50000) was added
(400 mL/slide) and incubated for 1h at RT in a humid chamber
in the dark. Slides were washed as above, covered with 50 %
glycerol, sealed and read using a fluorescence microscope (Leica
DMIRB DC200).
Parasites
The Uganda Palo Alto strain (FUP/C) was cultured in RPMI-
1640 supplemented with 0.5% albumax I (GibcoBRL-Invitrogen,
San Diego, CA). For ADCI assays, blood stage parasite cultures
were synchronized by at least two successive sorbitol treatments
followed, after maturation over 24 h, by floatation on 1% porcine
skin gelatin type A (Sigma).
Preparation of human blood monocytes
Blood monocytes (MN) were prepared from cytapheresis samples
obtained from healthy blood donors with no previous history of
malaria (Lecourbe Blood Bank, Paris, France). Peripheral blood
mononuclear cells (PBMC) were separated on Ficoll density
gradients J PREP (TechGen, Les Ulis, France) and washed in Ca
2+
and Mg
2+ free HBSS buffered with 10 mM HEPES (both from
GibcoBRL-Invitrogen). Cells were then distributed on polystyrene
96-well flat-bottomed culture plates (TPP, Trasadingen, Switzer-
land) and adherent MN were selected by incubation for 2 h at
37uC, in a humidified 5% CO2 atmosphere. More than 90% of
the adherent cells obtained in this manner were MN as estimated
by the non-specific esterase test (a-naphtyl acetate esterase; Sigma).
MN from each donor were tested prior to ADCI assays and only
those without direct inhibitory effect were used in assays.
ADCI in vitro assay
To wells containing 2610
5 MN purified as described above, 50 ml
of an asynchronous parasite culture at 0.5 % parasitemia and 4 %
hematocrit were added. Wells were then supplemented with test or
control antibodies (Ab) and the total volume adjusted to 100 ml
with culture medium. After 48 h and 72 h, 50 ml of culture
medium were added to each well and after 96 h the ADCI assay
was stopped and the final parasitemia was determined by light
microscopy on Giemsa-stained smears by counting $50,000 red
blood cells. For each Ab tested, duplicate wells included the
following controls 1) non-specific monocytic inhibition, both
MN+parasite, and MN+N-IgG+parasites and 2) direct inhibition
by control or test IgG, both N-IgG+parasites, and test Abs+par-
asites. PIAG and N-IgG were used at a final concentration of
1 mg/ml as positive and negative controls respectively. Immuno-
purified tests Abs were used at 15 mg/ml. The Specific Growth
inhibitory Index (SGI) which considers the parasite growth
inhibition due to the effect of test Abs cooperating with MN was
calculated as follows: SGI=1006[12(% parasitemia with MN
and test Abs/% parasitemia test Abs)/(% parasitemia with MN
and N-IgG/% parasitemia N-IgG)].
SUPPORTING INFORMATION
Figure S1 CD spectra of the peptides 45 (S1A) and 12 (S1B)
Found at: doi:10.1371/journal.pone.0000645.s001 (12.32 MB
TIF)
Figure S2 ELISA inhibition assay using anti-human peptide
specific antibodies. Binding of peptide specific antibodies to
peptides 76 (S2A) and 9 (S2B) absorbed on ELISA plates was
inhibited by incubating specific antibodies (1-2 mg/ml) with
peptides 14, 76 and 81 (S2A) and peptides 8 and 9 (S2B),
respectively (see Material and Methods). Peptides 14, 76 and 79
share NNM or MNN as sequence similarity while peptides 8 and 9
do not exhibit any apparent sequence similarity.
Found at: doi:10.1371/journal.pone.0000645.s002 (24.76 MB
TIF)
Table S1 Antibody response.
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PLoS ONE | www.plosone.org 7 July 2007 | Issue 7 | e645Found at: doi:10.1371/journal.pone.0000645.s003 (0.16 MB
DOC)
Table S2 Cross-reactivity determination in ELISA among
peptides tested in ADCI. The number in boxes represent the
ratio between the experimental and control ELISA OD.
Found at: doi:10.1371/journal.pone.0000645.s004 (0.36 MB
DOC)
Table S3 Structural feature and cellular location prediction of
the proteins containing the peptides whose specific antibodies were
tested in ADCI (Table 1).
Found at: doi:10.1371/journal.pone.0000645.s005 (0.05 MB
DOC)
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